Background Sodium-Glucose Cotransporter Protein 2 Inhibitors (SGLT2Is) are known for their cardiovascular and renoprotective benefits and are efficacious in managing Metabolic-Associated Steatotic Liver Disease (MASLD). However, limited data exist on their use in advanced liver disease, particularly liver cirrhosis. Aims To synthesize existing evidence on the efficacy and safety of SGLT2Is in patients with liver cirrhosis and to provide clinical guidance. Methods A systematic review and meta-analysis were conducted following the PRISMA 2020 Statement. Searches in major health databases identified studies where SGLT2Is were used in patients with cirrhosis. The analysis focused on prospective trials in decompensated cirrhosis and retrospective studies in compensated cirrhosis. Primary outcomes included the need for large-volume paracentesis (LVP) and mortality. Secondary outcomes assessed weight loss, loop diuretic dose reduction, residual ascites, acute kidney injury (AKI), hyponatremia, hepatic encephalopathy (HE), and urinary tract infections (UTIs). Results Ten studies (8 peer-reviewed) from 2020-2024 were included: 2 randomized controlled trials, 4 single-arm prospective trials, and 4 retrospective studies. SGLT2I use was associated with reduced LVP (RR 0.45, CI 0.31-0.66, p<0.001) and mortality (aHR 0.46, CI 0.38-0.55, p<0.001). Benefits included a 39 mg reduction in loop diuretic dose, 7 kg weight loss, and no significant increase in residual ascites, AKI, hyponatremia, HE, or UTIs. Conclusions SGLT2Is show promise in managing diuretic-resistant ascites and reducing mortality in liver cirrhosis without causing significant adverse events. Larger, randomized controlled trials are needed to validate these findings.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The source data are openly available and available in the cited studies included in our review

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript